Systemic sclerosis & Raynaud's

Anti-muscarinic 3 antibodies associate with a severe clinical phenotype in patients with systemic sclerosis

Rheumatology (Oxford)Published Cross-sectional study

Main finding · High GI severity (Medsger ≥2)Result — go to the resultOdds ratio 4.50 95% CI 1.11–18.18

Authors' conclusion

Anti-M3R antibodies are associated with a more severe GI phenotype and distinct extraintestinal and serological features in SSc patients.

Study context

Population
SSc patients in a cohort enriched for gastrointestinal (GI) symptoms52 (39.4%) anti-M3R positive
Participants
132 patients
Exposure
SSc patients with vs without high-titre anti-M3R antibodies
  • High-titre anti-M3Rn = 33
Outcome
GI and extraintestinal features associated with high-titre anti-M3R antibodies, incl. high GI severity (Medsger GI Severity Score ≥2)
Methodological detailscohort enriched for GI symptoms, high titre defined a priori as top quartile of anti-M3R titres, multivariable logistic regression
  • Cohort enriched for GI symptoms
  • High titre defined a priori as top quartile of anti-M3R titres
  • Multivariable logistic regression

Main finding

High GI severity (Medsger ≥2)

Odds ratio

4.50

95% CI 1.11–18.18

P = 0.035

By group

High-titre anti-M3Rvs Without high titres
OR 4.50 (95% CI 1.11–18.18); P = 0.035

As reported in the abstract

Observational data: associations, not effects.

Further findings

Diffuse disease

P = 0.023

Anti-RNPC3 antibodies

P = 0.036

OutcomeOR (95% CI)P value
Anti-U1RNP antibodiesMultivariable logistic regression20.36 (3.16–131.14)P = 0.002
OutcomeHigh-titre anti-M3RWithout high titresP value
Anti-U1RNP antibodies21.22.0%P = 0.001

Whole-gut transit studies and UCLA GIT 2.0 scores

Not different between the groups

Original publication

Anti-muscarinic 3 antibodies associate with a severe clinical phenotype in patients with systemic sclerosis. Rheumatology (Oxford). Published 12 April 2025. doi:10.1093/rheumatology/keaf197

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.